Immune response to hepatitis B vaccine in parenteral drug abusers

J. M. Rodrigo, M. A. Serra, L. Aparisi, A. Escudero, M. S. Gilabert, F. García, R. Gonzalez, J. A. del Olmo, A. H. Wassel, A. Artero, J. M. Nogueira

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Responsiveness was assessed to a programme of vaccination of hepatitis B vaccine in a cohort of 197 intravenous drug addicts (mean age, 23.7 years) and their antibody response was compared with that of 271 healthy controls (mean age, 24.2 years). All participants were seronegative for hepatitis B surface antigen (HBsAg) and antibody to HBsAg (anti-HBs). The vaccination schedule consisted of three intramuscular injections (deltoid area) at months 0, 1 and 2. Although 70% of parenteral drug abusers received the three doses of vaccination, only 43.6% were evaluable for immune response. Fifty-eight per cent of heroin addicts and 80% of controls had evidence of anti-HBs seroconversion at 1 month after vaccination (χ2 = 15.52, p < 0.001). Geometric mean antibody titres were also significantly higher in controls (69.1 IU l-1; confidence interval 95%, 56.83 and 84.04) than in parenteral drug abusers (18.2 IU l-1; confidence interval 95%, 12.85 and 25.73) (F = 20.951, p < 0.0001). The anti-HBs response was not influenced by coexistent anti-HBc, HCV antibody or HIV antibody seropositivity.

Original languageEnglish
Pages (from-to)798-801
Number of pages4
Issue number11
StatePublished - 1992
Externally publishedYes

Bibliographical note

Funding Information:
The authors wish to thank Marta Pulido for editorial assistance and copy editing. This project was supported by 'Oficina del Comisionado para la lucha contra la droga', Conselleria de Sanitat i Consum. Generalitat Valenciana.


  • Hepatitis B
  • intravenous drug addicts
  • vaccine


Dive into the research topics of 'Immune response to hepatitis B vaccine in parenteral drug abusers'. Together they form a unique fingerprint.

Cite this